A custom-made anti-tumor vaccine added to standard immunotherapy was twice as likely to shrink liver cancer as when a patient received immunotherapy alone, a new study shows.
Apr 9, 2024
0
64
A UC Davis Health study found that a single dose of Bacillus Calmette-Guérin (BCG), the vaccine for tuberculosis (TB), reduced liver tumor burden and extended the survival of mice with liver cancer. The study, published ...
Feb 21, 2024
0
19
A research team of Canadian and French scientists, led by INRS professor Maya Saleh, has been investigating immunotherapy resistance in certain patients with hepatocellular carcinoma (HCC) associated with steatotic liver ...
Feb 14, 2024
0
66
Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer worldwide but is often diagnosed at an advanced incurable stage. Yet, despite the urgent need for blood-based biomarkers for early detection, ...
Feb 12, 2024
0
0
Hepatocellular carcinoma (HCC) is a common human disease and one of the main causes of cancer-related death. The angiogenesis inhibitor Sorafenib (SORA) is commonly used in the treatment of advanced HCC as a first-line drug.
Feb 7, 2024
0
0
More than two-thirds of patients with hepatocellular carcinoma (HCC) who receive surgical interventions experience recurrence owing to lack of an established perioperative treatment. Now, researchers from Korea University ...
Feb 6, 2024
0
0
A team of researchers has found a causal link between the presence of oncofetal ecosystems (re-emergence of fetal program/features driven by the tumor) in the primary liver cancer hepatocellular carcinoma (HCC) and cancer ...
Jan 30, 2024
0
0
An editorial paper has been published in Oncoscience titled, "Lipiodol: from intrusion until exile from the tumor microenvironment."
Jan 8, 2024
0
0
Hepatocellular carcinoma (HCC) is the most common type of liver cancer. It is a major global health concern with rising rates, particularly in North Africa and East Asia. Although potentially curable in the early stages, ...
Dec 29, 2023
0
4
Liver cancer screening among patients with cirrhosis almost doubled when they were mailed a signed order from their specialist, according to a new study from the Perelman School of Medicine at the University of Pennsylvania. ...
Dec 22, 2023
0
0
